Background. This paper illustrates how data gathered from an existing screening programme against colorectal cancer can be used to produce new information on the natural history of colorectal cancer as well as the characteristics of the unhydrated Hemoccult II screening test. Methods. A mathematical model is used, which on the basis of prevalence and interval incidence data from a randomized screening project initiated in Funen County, Denmark, estimates the sensitivity of the screening test and the sojourn time of the disease. Results. The sensitivity of the Hemoccult is estimated at 62.1% and the mean sojourn time is estimated to be 2.1 years. Conclusions. The short sojourn time indicates that overall effectiveness of a Hemoccult II screening programme can be improved significantly by more frequent screening.
A common problem inherent in evaluating screening programmes is the lack of sufficient data on which to base appraisals. Such data are often needed in the early stages of implementation in order to generate information on which to base decisions on screening programme design and scale of implementation. Consequently, it becomes necessary to obtain estimates of the essential outcomes of alternative screening programme designs on the basis of available data. Estimates of the outcomes of alternative screening programmes require modelling based on knowledge about the natural history of the disease at issue as well as information on the relevant screening intervention. Such knowledge can be elicited from data gathered from existing screening programmes, as will be illustrated. In the present analysis modelling has been carried out on screening for colorectal cancer, but the model can be generalized to predict the effects of screening against other diseases.
Estimates of the sensitivity of the faecal occult blood test (Hemoccult II) for detection of colorectal cancer and the natural history of colorectal cancer are based on data collected from a randomized screening project for colorectal cancer which was initiated in Funen County, Denmark in August 1985. 1, 2 This paper describes the method used to estimate these core parameters and presents the results of the model estimations along with a discussion of their reliability. Below, an intuitive presentation of the model is given, followed by a description of the data needed as input into the estimation procedure. Subsequently, the estimated parameters are discussed in light of assumptions made on their interdependencies and the potential outcome of estimating such variables is highlighted. This is followed by a presentation of results and a discussion of their significance.
METHODS
The screening data used as input into the estimation procedures is information on prevalence at each screening round and interval incidence between screening rounds. The prevalence is here defined as the number of cancers detected as a result of the screening test at each screening round. Interval incidence is the number of cancers that surface between screening rounds normally due to the appearance of symptoms.
The basic idea in the following estimation is that such screening data from an existing screening programme is collected and used as input into a series of equations with two unknown parameters: the sensitivity of the test and the average sojourn time. The sojourn time is defined as the time period in which the cancer is detectable by the test but does not give clinical symptoms. The sensitivity of the screening test is the percentage of cancers present at the time of screening which are actually detected by the test.
The two parameters are estimated simultaneously using maximum likelihood estimation methods, such that the estimated prevalences and interval incidences based on these parameters correspond optimally to the prevalences and interval incidences observed in the randomized study. These estimates are subsequently used to predict the effects of alternative hypothetical screening programmes by entering the sensitivity estimate and the sojourn time estimate into the equations while varying variables such as screening interval and target age group. The model used in this analysis is based on a mathematical model developed by Day and Walter, 3 which has previously been used on data collected from the Health Insurance Plan study on screening for breast cancer, and as a basis for a cost effectiveness analysis of screening for cervical cancer. 4 
Required Data
As input into the equations used for estimating the sensitivity of the Hemoccult II test and the average sojourn time of colorectal cancer, prevalence data as well as incidence data may be used. Optimally, both types of information are used for estimation but in the case of, for example, cervical cancer where regression takes place, only incidence data is valid for use. Here, information on prevalence as well as incidence is used as input, assuming colorectal cancers do not regress.
Cancers detected at each screening round are registered according to sex and age of the patient. Only true positive test results are counted, thus eliminating those that turn out to be negative at the diagnostic test. For every screening round the cancers detected in each age/sex group along with the number of people screened in the specific age/sex group at each screening round are registered. From this information we calculated age-and sex-specific prevalence rates, i.e. the number of cancers per persons at risk in each group. This information is used as input into the estimation procedure.
Incident cases amongst individuals participating in the screening programme are registered. These are the cancers that are diagnosed between screening rounds amongst those participating in the screening round. For every incident case information is needed on the number of previous screening rounds the individual has participated in, along with information on how much time has passed since the last screening round. The cancer cases are again stratified by sex and age of the patient. The result for each group is a number of incident cases in the first year after the first screening round, in the second year after the screening round, and so forth. For the second, third and fourth screening round the same data are registered, resulting in a large number of categories in which the incident cases can be placed. Person years at risk in each category should also be noted. The person years at risk are registered by letting each individual move through the different categories, and for each year the individual spends in one category a person year is counted. The person years at risk are likewise divided into age and sex groups, giving incidence rates by category.
Another important variable is the background incidence which is defined as the frequency of entry into the presymptomatic but screen detectable stage. This incidence is obviously not observable, hence the incidence may be approximated by age-and sex-specific incidence rates found in national registries (see Appendix for Danish incidence rates used in this model). The incidence rates used in the estimation procedure are those registered in Denmark in the period 1983-1987. 5 The overall likelihood is obtained by taking the product of all categories as they are presented in the Appendix in Tables A1 and A2 . Using maximum likelihood techniques an estimate of the mean sojourn time and the sensitivity of the Hemoccult II test is determined such that the estimated prevalence and incidence rates in each sex and age category (given the age-and sex-specific background incidences) correspond optimally to those prevalence and incidence rates that have been observed in each age and sex category.
Sojourn Time and Sensitivity
Recent studies in patients with symptomatic colorectal cancer found that Hemoccult II had a rather low sensitivity with results ranging from 69.2% 6 to 88.8%. 7 Recent reports from screening programmes indicate that the sensitivity for asymptomatic cancer is, as one would expect, lower. Estimation of the sensitivity amongst asymptomatic individuals is, however, made difficult because Hemoccult-negative individuals do not undergo examinations of the colon. Consequently, it has been necessary to assume that cancers or adenomas surfacing within a specified period following a negative screening test are false negatives. In the study by Ahlquist et al. 8 patient groups with anticipated higher-than-average risk of colorectal neoplasia were studied. Test sensitivities were estimated by factoring into the estimation an approximation of missed cancers based on close follow-up enquiries. Hemoccult sensitivity at 1, 1.5 and 3 years of follow-up were as low as 33%, 29% and 25%. In Mandel et al. 9 the sensitivity was defined as a case diagnosed within 12 months following a negative screening test. The sensitivity for the non-rehydrated Hemoccult test was significantly different from that of Ahlquist et al., reaching 80.8%. Allison et al. 10 report a sensitivity of 37.1%. The performance of the test was evaluated by identifying screened patients who had carcinomas in the 2 years following screening. Kewenter et al. 11 report a sensitivity of 28% over a period of 27 months, and Castiglione et al. 12 report the following sensitivities from a population-based screening programme in the province of Florence: 69.4% (one-year follow-up), 61.8% (2 years of follow-up) and 57.7% (3 years of follow-up).
In the randomized controlled trial on Funen in Denmark the overall sensitivities over the first three screening rounds were 66.1% after one year of followup and 43.8% after 2 years of follow-up. These figures lie in the same order of magnitude as those of Allison et al. and Castiglione et al.
The sensitivity of a test is often, as is done in the analyses above, estimated independently of the sojourn time. In these analyses it is assumed that all cancers that surface within 1 or 2 years of the screening test giving a negative result must be false negatives. This is not necessarily the case, however, since the incident cases surfacing in these time periods may be cases with short sojourn times which developed after the screening test was performed. Hence, such estimation methods are likely to underestimate the sensitivity of the test in that they incorporate recently initiated cases as false negatives. In principle the sensitivity of the Hemoccult test and the average duration of sojourn time for colorectal cancer must be estimated simultaneously and cannot be estimated independently of each other. This is the method used in the present analysis.
The sensitivity of the test is here described through two parameters, one is the sensitivity rate, which is the percentage of cancers prevalent at the time of the test that are being detected by the test. The other parameter is the mean sojourn time which is the mean time period in which the test technically can detect the cancer. The Hemoccult test looks for blood in the stools, so in this context the sensitivity tells us how large a proportion of those people who have colorectal cancer have detectable blood in the stools. The mean sojourn time, on the other hand, is the mean time period in which the patients are bleeding before being diagnosed.
The starting point of the sojourn time is the earliest point of detection and sojourn time therefore depends on the test's ability to detect the cancer (Figure 1 ). The length of sojourn time may tell us something about the natural history of the disease, i.e. the time it takes for the cancer to develop into a symptomatic stage (how far sojourn time extends to the right on the time axis) and it may tell us something about the sensitivity of the test (how far it extends to the left). An inefficient test may involve zero sensitivity at early stages, and consequently produce a short sojourn time. A test's sensitivity is thus simultaneously described by the length of sojourn time and the sensitivity parameter.
Above, sojourn time is defined as the time period in which the cancer is asymptomatic but detectable by screening test. This phrasing is commonly used in the literature, but more precisely the endpoint of sojourn time is the time of diagnosis due to symptoms. The time that occurs between appearance of symptoms and signs and the time of diagnosis is thus encompassed in the sojourn time. This is the only realistic time period to operate with, since the appearance of a cancer is registered at the time of diagnosis, and not necessarily the time of appearance of symptoms. What may be called medico-social errors (encompassing all the reasons for late diagnosis) are consequently included in this time period, which makes sojourn time not only test-specific but also country-specific. Countries have different traditional diagnostic practices and may be more or less efficient at diagnosing the cancer from symptoms. Consequently, sojourn time, although related to the natural history of the disease, is at the same time dependent on FIGURE 1 Lead time and sojourn time traditional diagnostic methods and medical practice in general in specific countries as well as the characteristic of the test used.
In the presented estimations it is assumed that the sojourn time is exponentially distributed. This distribution does not necessarily provide the best fit to the observed data. The exponential distribution was chosen because of its mathematical features. Including other distributions such as the log-normal distribution in the analysis, could be the focus of future research.
Lead time is that part of the sojourn time with which the diagnosis has been brought forward by screening (Figure 1) . The longer the lead time of the screendetected cancers, the earlier the detection. If the sojourn time distribution of the initiated cancers is exponential the lead time distribution of the cancers detected at each screening round can be estimated, since it will also be exponential. Moreover, the average lead time of the screen-detected cancers will be equal to the average sojourn time of all the initiated cancers. This relationship is inherent in the characteristics of the exponential distribution and will not be true for any other distribution. For mathematical proof of this statement see Day and Walter. 1 
RESULTS
The county of Funen has 140 000 inhabitants aged 45-74 years. Screening with Hemoccult II was offered to 30 967 people and another 30 966 were selected as controls. No stratification was used. Those with known colorectal cancer, adenomas and metastases from all cancers were excluded before randomization. Screenings were offered every 2 years by written invitation and included Hemoccult II slides with detailed instructions for diet (no red meat or fresh fruit) and medicine (no iron preparations, vitamin C, aspirin, or other nonsteroid antirheumatics) for 3 days before stool sampling. Two samples were to be taken from each of three consecutive stools. The slides were developed without rehydration and were considered positive when one or more slides turned blue. Polyps detected were treated and the patients were entered into a follow-up programme. For a more detailed description of the randomized controlled trial see Kronborg et al. 13 The reason for treating polyps is that such treatment is expected to reduce the incidence of cancers. Such an effect is likely to be inherent in these screening data and could potentially confound estimates of the sojourn time and sensitivity for colorectal cancer. The number of polyps (у1 cm in diameter) found at the first four screening rounds were 68, 61, 41 and 44. 13 Stryker et al.
14 estimated the cumulative risk of diagnosis of cancer at a polyp site at 5, 10 and 20 years to be 2.5%, 8% and 24% respectively. Using these conversion rates of large polyps (у1 cm in diameter) we estimated the potential reduction in incidence due to the detection of polyps and found that within the maximum follow-up period of 8 years, seven to eight cancers might be avoided due to polypectomy of large adenomas. Large adenomas constituted 70% of all adenomas detected. In patients with only a single small tubular adenoma that is only mildly or moderately dysplastic, surveillance is thought to be of little value because the risk of cancer is low. [15] [16] [17] As a consequence, the estimated impact of detection of small adenomas was calculated at zero.
We considered seven to eight cancers to be a small number compared with the number of cancer cases on which we base our estimates (227) and concluded that the impact of polypectomy could not potentially confound the estimates of sojourn time and sensitivity of early colorectal cancer in a significant way.
The observed results over the initial four screening rounds of the randomized trial in Funen County are listed in Table 1 . The category 'incidence in the following years' represents incident cases amongst those who initially participated in the screening programme and later ignored an invitation. These individuals continued to be part of the study, and consequently cancers that developed in this group were registered. See the Appendix for a more detailed account of the observed incidence and prevalence rates (Tables A1 and A2 ).
The maximum likelihood estimation based on the screening data from the Danish randomized study produced a sensitivity of the Hemoccult II test of 62.1% (SE = 0.181) and a mean sojourn time of 2.1 years (SE = 0.181); Cor = -0.895; LogL = -7.519. The assumption that the sojourn time distribution is exponential leads to the average sojourn time being equal to the average lead time, as mentioned earlier.
The average lead time of the screen detected cancers is thus 2.1 years.
The correlation coefficient is, not surprisingly, numerically large (-0.895) which means that there is a trade off between the parameters when these are to explain the observed screening data. Such a trade off results in a long confidence elipsoid as depicted in Figure 2 .
The confidence interval is constructed by calculating the log likelihood over a range of values of the sensitivity and mean sojourn time and constructing a region of values for which the log likelihood is less than a certain value from the maximum value (-7.519). The confidence region is thus given by: {(s*, SJT*) such that 2[logL(s*, SJT*) -logL(s*, SJT*)] Ͻ χ 2,α 2 }, where s is the sensitivity and SJT is the mean sojourn time.
In Figure 2 the 95% confidence interval is drawn for the two parameters. The four points plotted on the contour indicate the extreme values for the sensitivity when the mean sojourn time is held constant at 2.1 years and the extreme values for the mean so-journ time when the sensitivity is held constant at 62.1%, respectively. Table 2 presents estimates for incidence and prevalence rates predicted by the model when the sensitivity is 62.1% and the mean sojourn time is 2.1 years. When estimated and observed prevalences and interval incidences are compared (Tables 1 and 2 
Sensitivity Analysis
The relatively bad fit (0.1 Ͻ P Ͻ 0.25) is possibly due to random errors in the observed data relative to the expected pattern of events. It is expected that the prevalence rate is high at the first screening round and that the prevalence will stabilize to a lower level at subsequent screening rounds. The observed prevalence follows this pattern if one focuses on the first, third and fourth screening round. However, the prevalence at the second screening round is lower than expected. (This discrepancy cannot be explained by movements in the age distribution of the screened population.) Moreover, the interval incidence rate in the subsequent year of a screening round should be significantly lower relative to the incidence expected if no screening had taken place, and the incidence rate is then expected to rise in subsequent years if no further screening takes place. Not all observations from the randomized study follow this pattern.
Due to these irregular observations introducing other distributions (such as the Weibull or the log normal) into the model would not improve the lack of fit. Consequently such efforts were abandoned. However, estimations of different combinations of these 'irregular' observations are excluded in the input, in order to see what effect such an elimination has on the parameter estimates and the goodness of fit (Table 3) .
The exclusion of irregular observations does not alter the sensitivity estimate significantly. The variation is between 56.3% and 61.8%. The effect is thus a slight decrease in sensitivity. The mean sojourn time estimate rises to values between 2.21 years and 2.78 years. The elimination of observations increases the goodness of fit. These results indicate that the true estimates of the sensitivity and mean sojourn time probably do not lie in the extreme ends of the confidence region (Figure 2 ). 
DISCUSSION
The average sojourn time and sensitivity estimates presented here are overall estimates, i.e. not age-dependent or dependent on screening round. Age-dependent estimates could not be obtained since the relatively small size of the dataset did not allow estimations on subgroups. Sensitivity estimates depending on screening round were not looked into since it was assumed that the sensitivity at the first screening round would only be slightly higher than at subsequent screening rounds, due to the relative short overall sojourn time and the rather low overall sensitivity. The sensitivity rate of 62.1% is closer to the estimated sensitivity obtained using the same data and a follow-up period of one year (66.1%) than when a 2-year follow-up period is used which produces a markedly lower estimate (43.8%). Using the method of follow-up periods for estimating sensitivities is not incorrect, since it may well be a good method with which to compare the effectiveness of different tests assuming that one uses similar follow-up periods. The analysis presented here, does however give more information as to how the test obtains its effectiveness; Through a high sensitivity? Or through a long sojourn time?
Much effort has been focused on improving the overall effectiveness of colorectal cancer screening programmes, and some tests such as the Hemoccult II Sensa and the HemoSelect 10 have been proven to have significantly higher overall sensitivity rates than the Hemoccult II. It is not clear, however, whether this is due to an improved ability to detect very small amounts of blood (indicating a longer average sojourn time assuming that the bleeding is initially insignificant) or a general improvement in the detection of blood when it is present (indicating an improved sensitivity rate). Analyses like the one presented here can answer these questions and thus give a better base on which to compare alternative screening tests. The sojourn time and sensitivity estimates jointly give an indication of the appropriate screening interval to implement. A long sojourn time will ceteris paribus, indicate longer screening intervals, while a short sojourn time signals the importance of frequent screening. The relatively short sojourn time estimated for the Hemoccult II test indicates that a more frequent application of this test will improve effectiveness significantly. The low sensitivity of the Hemoccult II test in the detection of polyps further justifies this conclusion (see Appendix for calculations). The Hemoccult II test applied more often than every 2 years may prove to be a more effective (and possibly less expensive) screening method relative to alternative methods using more advanced test techniques. (The specificity of the Hemoccult II was as high as 99.5% in this trial. Very low specificities have been observed for alternative FOB tests.) CONCLUSION To our knowledge the mean sojourn time has not previously been estimated for the Hemoccult II test on the basis of screening data. Instead, figures varying from 4 years to one year have been used as inputs into simulation models developed by Eddy 18 and the Office of Technology Assessment. 19 The aim of this paper has been to provide new information about, and insight into, the interaction of the natural history of colorectal cancer and the sensitivity of the Hemoccult II test and their use in comparing the effectiveness of screening programmes. The estimated mean sojourn time (2.1 years) and the estimated sensitivity (62.1%) vary markedly within the 95% confidence region, and the estimates must therefore be treated with some caution. Nevertheless, these estimates provide new knowledge of the effectiveness of the unhydrated Hemoccult II test in detecting colorectal cancer, and suggest that overall sensitivity may significantly be improved by administering this test more frequently.
APPENDIX

Polyp Sensitivity
In an effort to estimate the magnitude of the polyp sensitivity of the Hemoccult II test we made some crude calculations using screening data and model parameter estimates. In all, 95 cancers were detected in the initial four screening rounds of this trial. According to the estimates in this paper this must imply that 153 cancers were present at the time of screening (153*0.621 = 95). This means that 58 preclinical invasive cancers were false negatives. Assuming that these 58 cancers all belonged to the group of 110 cancers that within 2 years of screening developed into clinical cancer, there remains 74 cases that entered the preclinical cancerous phase after screening. Initially assuming that all these cases were preceded by the presence of large adenomas and further assuming that such adenomas were present at the time of screening, we can calculate the sensitivity of the Hemoccult II test in detecting polyps larger than 1 cm in diameter. Stryker et al. 14 found that 2.5% of large adenomas developed into invasive carcinoma within 5 years. This entails that approximately 1% of all adenomas prevalent at one time would develop into cancers within 2 years, indicating that around 5200 large polyps (52/0.01) must have been prevalent at the screening rounds. The number of large adenomas detected was 214, giving a sensitivity estimate of 4.1% (214/5200).
This estimate was based on the assumption that the adenoma-carcinoma sequence is true for all cancer cases. There is however evidence of this not being true. Eide 20 defined the annual conversion rate as number of cancers occurring each year as a percentage of all adenoma-bearing individuals (based on autopsy studies), assuming that all colorectal cancers develop from preexisting adenomas. Eide arrived at an annual conversion rate of 3%. This conversion rate contrasts with Stryker et al.'s findings, which are based on retrospective data of polyp patients who did not undergo polypectomy. Here the average annual conversion rate was 1.2%. Comparing these two estimates implies that the percentage of cancers that develop from pre-existing adenomas lies in the 40% range (1.2/3). Re-estimating the sensitivity assuming that only 40% of the 52 cancers that entered the pre-clinical cancerous phase after screening were preceded by adenomas, gives a new estimate of 10.2%.
Realizing that this estimate is only an approximation and based on rather crude estimations, it nevertheless gives an order of magnitude which is confirmed by other studies. Demers et al. 21 calculated an overall sensitivity rate for polyps of 3% and a sensitivity for large adenomas of 11%. Windeler et al. 22 estimated a sensitivity of 20% for large adenomas, whereas Li et al. 23 and Bang et al. 24 found overall sensitivity estimates (including small and large adenomas) of 8% and 5% respectively. Several authors have however calculated higher overall polyp sensitivities in the range of 16-42%. [25] [26] [27] [28] [29] ( Tables A1-A3) . 
